[96a5a0]: / output / allTrials / identified / NCT03941873_identified.json

Download this file

819 lines (819 with data), 36.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
{
"info": {
"nct_id": "NCT03941873",
"official_title": "A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer",
"inclusion_criteria": "* Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic HCC/gastric cancer/GEJ cancer\n* Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments\n* Age ≥ 18 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)\n* Adequate organ function\n* Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of study drug(s), and have a negative serum pregnancy test ≤ 7 days of first dose of study drug(s)\n* Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drug(s)\n* Failed current standard-of-care treatment, or standard-of-care treatment is considered not appropriate at present\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Active leptomeningeal disease or uncontrolled brain metastasis\n* Active autoimmune diseases or history of autoimmune diseases that may relapse\n* Any active malignancy ≤ 2 years before first dose of study drug(s)\n* History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases including pulmonary fibrosis or acute lung diseases\n* Severe chronic or active infections (including tuberculosis infection) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to first dose of study drug(s)\n* Known history of human immunodeficiency virus (HIV) infection\n* Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers.\n* Any major surgical procedure requiring general anesthesia ≤ 28 days before the first dose of study drug(s)\n* Prior allogeneic stem cell transplantation or organ transplantation\n* Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)\n* Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring\n* Any systemic chemotherapy within 28 days of the first dose of study drug(s) or hormone therapy, targeted therapy, or any investigational therapies\n* Toxicities (as a result of prior anticancer therapy) that have not recovered to baseline or stabilized, except for adverse events not considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory abnormalities)\n* Inability to swallow capsules or disease significantly affecting gastrointestinal function\n* Pregnant or breastfeeding woman\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
"miscellaneous_criteria": "Key"
},
"inclusion_lines": [
{
"line": "* Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic HCC/gastric cancer/GEJ cancer",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "cancer confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "unresectable",
"criterion": "resectability",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "locally advanced",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "locally advanced"
}
]
},
{
"exact_snippets": "metastatic",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "metastatic"
}
]
},
{
"exact_snippets": "HCC/gastric cancer/GEJ cancer",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"HCC",
"gastric cancer",
"GEJ cancer"
]
}
]
}
]
},
{
"line": "* Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments",
"criterions": [
{
"exact_snippets": "Able to provide written informed consent",
"criterion": "written informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "can understand and agree to comply with the requirements of the study",
"criterion": "understanding and agreement to comply",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "can understand and agree to comply with ... the schedule of assessments",
"criterion": "understanding and agreement to comply with schedule of assessments",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "* Age ≥ 18 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)",
"criterions": [
{
"exact_snippets": "Age ≥ 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
},
{
"exact_snippets": "legal age of consent in the jurisdiction",
"criterion": "legal age of consent",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": "legal age of consent in the jurisdiction"
}
]
}
]
},
{
"line": "* Adequate organ function",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of study drug(s), and have a negative serum pregnancy test ≤ 7 days of first dose of study drug(s)",
"criterions": [
{
"exact_snippets": "Females of childbearing potential",
"criterion": "gender and reproductive status",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "female of childbearing potential"
}
]
},
{
"exact_snippets": "willing to use a highly effective method of birth control",
"criterion": "birth control usage",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
},
{
"exact_snippets": "duration of the study, and ≥ 120 days after the last dose of study drug(s)",
"criterion": "birth control duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 120,
"unit": "days"
}
]
}
}
]
},
{
"exact_snippets": "negative serum pregnancy test ≤ 7 days of first dose of study drug(s)",
"criterion": "serum pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
},
{
"requirement_type": "timing",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 7,
"unit": "days"
}
]
}
}
]
}
]
},
{
"line": "* Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drug(s)",
"criterions": [
{
"exact_snippets": "Nonsterile males must be willing to use a highly effective method of birth control",
"criterion": "birth control usage",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
},
{
"exact_snippets": "for the duration of the study and for ≥ 120 days after the last dose of study drug(s)",
"criterion": "birth control usage duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 120,
"unit": "days"
}
]
}
}
]
}
]
},
{
"line": "* Failed current standard-of-care treatment, or standard-of-care treatment is considered not appropriate at present",
"criterions": [
{
"exact_snippets": "Failed current standard-of-care treatment",
"criterion": "standard-of-care treatment",
"requirements": [
{
"requirement_type": "outcome",
"expected_value": "failed"
}
]
},
{
"exact_snippets": "standard-of-care treatment is considered not appropriate at present",
"criterion": "standard-of-care treatment",
"requirements": [
{
"requirement_type": "appropriateness",
"expected_value": false
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Active leptomeningeal disease or uncontrolled brain metastasis",
"criterions": [
{
"exact_snippets": "Active leptomeningeal disease",
"criterion": "leptomeningeal disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "uncontrolled brain metastasis",
"criterion": "brain metastasis",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "* Active autoimmune diseases or history of autoimmune diseases that may relapse",
"criterions": [
{
"exact_snippets": "Active autoimmune diseases",
"criterion": "autoimmune diseases",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "history of autoimmune diseases that may relapse",
"criterion": "autoimmune diseases",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "relapse potential",
"expected_value": true
}
]
}
]
},
{
"line": "* Any active malignancy ≤ 2 years before first dose of study drug(s)",
"criterions": [
{
"exact_snippets": "Any active malignancy ≤ 2 years before first dose of study drug(s)",
"criterion": "active malignancy",
"requirements": [
{
"requirement_type": "time since last occurrence",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "* History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases including pulmonary fibrosis or acute lung diseases",
"criterions": [
{
"exact_snippets": "History of interstitial lung disease",
"criterion": "interstitial lung disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "noninfectious pneumonitis",
"criterion": "noninfectious pneumonitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "uncontrolled diseases including pulmonary fibrosis",
"criterion": "pulmonary fibrosis",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled diseases including ... acute lung diseases",
"criterion": "acute lung diseases",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
}
]
},
{
"line": "* Severe chronic or active infections (including tuberculosis infection) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to first dose of study drug(s)",
"criterions": [
{
"exact_snippets": "Severe chronic or active infections (including tuberculosis infection)",
"criterion": "infections",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
},
{
"requirement_type": "activity",
"expected_value": "chronic or active"
}
]
},
{
"exact_snippets": "requiring systemic antibacterial, antifungal, or antiviral therapy",
"criterion": "systemic therapy",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"antibacterial",
"antifungal",
"antiviral"
]
}
]
},
{
"exact_snippets": "within 14 days prior to first dose of study drug(s)",
"criterion": "time since last therapy",
"requirements": [
{
"requirement_type": "time",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Known history of human immunodeficiency virus (HIV) infection",
"criterions": [
{
"exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers.",
"criterions": [
{
"exact_snippets": "Untreated chronic hepatitis B",
"criterion": "chronic hepatitis B",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "untreated"
}
]
},
{
"exact_snippets": "chronic hepatitis B virus (HBV) carriers",
"criterion": "chronic hepatitis B virus (HBV) carriers",
"requirements": [
{
"requirement_type": "carrier status",
"expected_value": true
}
]
}
]
},
{
"line": "* Any major surgical procedure requiring general anesthesia ≤ 28 days before the first dose of study drug(s)",
"criterions": [
{
"exact_snippets": "major surgical procedure requiring general anesthesia ≤ 28 days before the first dose of study drug(s)",
"criterion": "major surgical procedure",
"requirements": [
{
"requirement_type": "time since procedure",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Prior allogeneic stem cell transplantation or organ transplantation",
"criterions": [
{
"exact_snippets": "Prior allogeneic stem cell transplantation",
"criterion": "allogeneic stem cell transplantation",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "organ transplantation",
"criterion": "organ transplantation",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
"criterions": [
{
"exact_snippets": "Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg",
"criterion": "systolic blood pressure",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 150,
"unit": "mmHg"
}
}
]
},
{
"exact_snippets": "Inadequately controlled hypertension ... and/or diastolic blood pressure > 100 mmHg",
"criterion": "diastolic blood pressure",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 100,
"unit": "mmHg"
}
}
]
}
]
},
{
"line": "* Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring",
"criterions": [
{
"exact_snippets": "Bleeding or thrombotic disorders",
"criterion": "bleeding or thrombotic disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "use of anticoagulants such as warfarin or similar agents",
"criterion": "use of anticoagulants",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "requiring therapeutic international normalized ratio (INR) monitoring",
"criterion": "therapeutic INR monitoring",
"requirements": [
{
"requirement_type": "requirement",
"expected_value": false
}
]
}
]
},
{
"line": "* Any systemic chemotherapy within 28 days of the first dose of study drug(s) or hormone therapy, targeted therapy, or any investigational therapies",
"criterions": [
{
"exact_snippets": "Any systemic chemotherapy within 28 days of the first dose of study drug(s)",
"criterion": "systemic chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
]
},
{
"exact_snippets": "hormone therapy, targeted therapy, or any investigational therapies",
"criterion": "hormone therapy, targeted therapy, investigational therapies",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Toxicities (as a result of prior anticancer therapy) that have not recovered to baseline or stabilized, except for adverse events not considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory abnormalities)",
"criterions": [
{
"exact_snippets": "Toxicities (as a result of prior anticancer therapy) that have not recovered to baseline or stabilized",
"criterion": "toxicities from prior anticancer therapy",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": "recovered to baseline or stabilized"
}
]
},
{
"exact_snippets": "adverse events not considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory abnormalities)",
"criterion": "adverse events",
"requirements": [
{
"requirement_type": "safety risk",
"expected_value": false
}
]
}
]
},
{
"line": "* Inability to swallow capsules or disease significantly affecting gastrointestinal function",
"criterions": [
{
"exact_snippets": "Inability to swallow capsules",
"criterion": "ability to swallow capsules",
"requirements": [
{
"requirement_type": "ability",
"expected_value": false
}
]
},
{
"exact_snippets": "disease significantly affecting gastrointestinal function",
"criterion": "gastrointestinal function",
"requirements": [
{
"requirement_type": "impact",
"expected_value": "significant"
}
]
}
]
},
{
"line": "* Pregnant or breastfeeding woman",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding woman",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
"criterions": [
{
"exact_snippets": "Other protocol defined Inclusion/Exclusion criteria",
"criterion": "protocol defined criteria",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "Key",
"criterions": [
{
"exact_snippets": "Tissue from tumor must be available",
"criterion": "tumor tissue",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
},
{
"exact_snippets": "Tissue from tumor ... > 2 cm in diameter.",
"criterion": "tumor tissue",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "cm"
}
}
]
}
]
}
],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "Key",
"criterions": [
{
"exact_snippets": "Tissue from tumor must be available",
"criterion": "tumor tissue",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
},
{
"exact_snippets": "Tissue from tumor ... > 2 cm in diameter.",
"criterion": "tumor tissue",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "cm"
}
}
]
}
]
}
]
}